Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2007

Optherion Obtains Rights to Use Chromosome 10 Genetic Variations in AMD Diagnostics

  •  Optherion licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10.

    In 2005, scientists at the University of Pittsburgh published research in the American Journal of Human Genetics  showing a link between Chromosome 10, specifically the LOC387715 and HTRA1 genes, and AMD.

    “The licensing agreement with the University of Pittsburgh adds significantly to our portfolio,” says Colin J. Foster, president and CEO of Optherion. “Optherion is now in a position to develop diagnostic tests based upon the most recently discovered genetic associations of dry AMD. We are optimistic that the innovative discoveries we are licensing will lead to diagnostic tests that can help change the current paradigm of AMD risk assessment and patient care.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »